ACC Media Center/X
Aug 29, 2025, 19:08
American College of Cardiology Highlights LoDoCo2 Trial on Colchicine, Blood Cancer Risk, and Heart Health
ACC (American College of Cardiology) Media Center posted on X:
”Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published in JACC and presented at ESC Congress.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 14:42Salih Ehsan: Bradykinin-Mediated Transfusion Reactions in Patients on ACE Inhibitors
-
Apr 23, 2026, 14:39Mona Alfaraj: Don’t Miss the Chance to Be Part of the 2nd International Hematology and Hemostasis Conference
-
Apr 23, 2026, 14:11Emerging Contributions to Hemostasis from Recipients of the Christine Lee Young Researcher Awards – WFH
-
Apr 23, 2026, 13:52Joffrey Feriel: A Revised ISTH Definition of Disseminated Intravascular Coagulation
-
Apr 23, 2026, 13:39Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation
-
Apr 23, 2026, 13:35Jecko Thachil: Risk Assessment and Clinical Management of Nephrotic Syndrome–Associated Thrombosis
-
Apr 23, 2026, 12:18Mona Ranade: A Contemporary Framework for Managing Right Heart Thrombus in PE
-
Apr 23, 2026, 11:59Strengthening Hemophilia Care Through Collaboration and Commitment in India at IHC X 2026 – Hemophilia Federation India
-
Apr 23, 2026, 08:16David Ferreira: Identifying the True Drivers of Recurrent Thrombosis